Wipro Releases the ‘State of IT Infrastructure 2020’ Report
Findings from the report reveal 75% organizations require increased infrastructure budget for new tools, technologies…
6 years ago
Wire Stories
IT Glue 2020 Global MSP Benchmark Survey Reveals Impact of Pandemic on State of the Industry
Survey shows nearly three-fourths fear a second lockdown; Revenue and M&A interest dip amid uncertainty…
6 years ago
FPT Partners with World’s Largest Deep Learning Institute to Foster AI Development
HANOI, Vietnam--(BUSINESS WIRE)--FPT, Vietnam’s largest IT service provider, has signed a strategic partnership agreement with…
6 years ago
Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders
− These Data Demonstrate Breadth of Takeda’s Portfolio and Pipeline with Three Hematology Presentations at…
6 years ago
Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma
- The primary endpoint (antitumor effect) was achieved - No new safety concerns were identified in the…
6 years ago
Mitsubishi Electric Announces End of Production of TFT-LCD Modules
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will end the production of…
6 years ago
AVITA Medical Limited Proposed Redomiciliation to the United States of America – Results of Scheme Meeting
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited ACN 058 466 523 (Company) is pleased…
6 years ago
BORN Group Extends Its Partnership With Akeneo Globally, to Augment Its Experience Management & Enterprise Commerce Offerings
Tapped as BORN’s exclusive PIM partner, Akeneo’s Product Experience Management (PXM) capabilities well complement BORN’s…
6 years ago
Gunfire Reborn, a FPS+Roguelite game, is on Steam “Top Sellers”
HONG KONG--(BUSINESS WIRE)--Recently, FPS+Roguelite game Gunfire Reborn developed by Duoyi (Hong Kong) Interactive starts Early…
6 years ago
New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
Data from a Phase II trial show a regimen of Truxima® (biosimilar rituximab), lenalidomide and…
6 years ago